Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-01-11
2008-10-21
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S236100, C514S002600, C514S012200, C530S350000, C530S412000
Reexamination Certificate
active
07438921
ABSTRACT:
Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as abotulinumneurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.
REFERENCES:
patent: 5298019 (1994-03-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6261572 (2001-07-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 6667041 (2003-12-01), Schmidt
patent: 7179474 (2007-02-01), First
patent: 2003/0054975 (2003-03-01), Voet
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 2004/0213811 (2004-10-01), Ackerman
patent: WO 95/05842 (1995-03-01), None
patent: WO 96/33273 (1996-04-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 00/10598 (2000-03-01), None
patent: WO 00/15245 (2000-03-01), None
patent: WO 00/57897 (2000-03-01), None
patent: WO 00/74703 (2000-05-01), None
patent: WO 01/21213 (2001-03-01), None
patent: WO 03/011333 (2003-02-01), None
Aoki, K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia Sep. 2003;23(7):649.
Bigalke, H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke, H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz, T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Blugerman, G., et al.,Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg May 2003;29(5):557-9.
Borodic et al.,Pharmacology and Histology fo the therapeutic Application of Botulinum Toxin, Therapy With Botulinum Toxin, Ed. Jankovic, J., et al., Marcel Dekker, Inc., (1994), p. 150.
Boyd et al., Movement Disorders, vol. 10, No. 3 (1995), p. 376.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas, Lancet 345;1008-1012:1995.
Bushara, K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507.
Childers et al., (2002), American Journal of Physical Medicine & Rehabilitation, 81:751-759.
Coffield et al.,Site and Action of Botulinum Neurotoxin, Therapy With Botulinum Toxin, Ed. Jankovic, J., et al., Marcel Dekker, Inc., (1994), p. 5.
Dabrowski, E., et al.,Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome, Ann Neurol Sep. 2002;52(3 Supp 1):S157.
Doggweiler, R., et al.,Botulinum toxin type A causes diffuse and highly selective atrophy of rat prostate, Neurourol Urodyn 1998;17(4):363.
Fung, L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58; 672-684:1998.
Goldman, (2000), Aesthetic Plastic Surgery Jul.-Aug. 24(4):280-282.
Gonelle-Gispert, Carmen, et al.,SNAP-25a and -25b Isoforms are Both Expressed in Insulin-Secreting Cells and Can Function in Insulin Secretion, Biochem J. (1999) 339 (pt 1); pp. 159-165.
Habermann, E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann, E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann, E.,Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Heckmann, M., et al.,Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol Apr. 2002;46(4):617-9.
Jost, W.,Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis Sep. 2002;17(5):298-302.
Katsambas, A., et al.,Cutaneous diseases of the foot: Unapproved treatments, Clin Dermatol Nov.-Dec. 2002;20(6):689-699.
Li, Y., et al.,Sensory and motor denervation influences epidermal thickness in rat foot glabrous skin, Exp Neurol 1997;147:452-462 (see p. 459).
Marchese-Ragona, R. et al.,Management of Parotid Sialocele With Botulinum Toxin, The Laryngoscope 109 (Aug. 1999):1344-1346.
Ahn, Jeffrey, et al.,Botulinum toxin for masseter reduction in asian patients, Arch Facial Plast Surg, vol. 6, May/Jun. 2004, pp. 188-191.
Childers, Martin K., et al.,Botulinum toxin use in piripormis muscle syndrome: a double-blind study, Arch Phys Med Rehabil, 2000, 81(9):1289, Poster 142.
Fishman, L.,Myobloc in the treatment of piriformis syndrome: a dose-finding study, Naunyn Schmiedebergs Arch Pharmacol, Jun. 2002, 365 (Suppl 2):R20.
Fishman, L.,Myobloc in the treatment of piriformis syndrome—a dose-finding study, Pain Med, 2002, 3(2), pp. 182-183 (Abstract).
Lee, Hyun-Jeong, et al.,Botulinum toxin A for aesthetic contouring of enlarged medial gastrocnemius muscle, Dermatol Surg, 2004, 30, pp. 867-871.
Moyer, E., et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, being chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin,” edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann, Markus, et al.,Botulinum Toxin Type A in the Treatment of Focal, Axillary and Palmar Hyperhidrosis and Other Hyperhidrotic Conditions, European J. Neurology 6 (Supp 4): S111-S1150:1999.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393, 1997.
Rogers, J., et al.,Injections of botulinum toxin A in foot dystonia, Neurology Apr. 1993;43(4 Suppl 2).
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1987.
Schantz, E.J., et al.,Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine, Microbiol Rev. 56;80-99:1992.
Senior, M.,Botox and the management of pectoral spasm after subpectoral implant insertion, Plastic and Recon Surg, Jul. 2000, 224-225.
Sevim, S., et al.,Botulinum toxin-A therapy for palmar and plantar hyperhidrosis, Acta Neurol Belg Dec. 2002;102(4):167-70.
Singh,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976).
Sloop, R. et al.,Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated before 2 weeks before use, Neurology 48 (Jan. 1997):249-53:1997.
Suputtitada, A.,Local botulinum toxin type A injections in the treatment of spastic toes, Am J Phys Med Rehabil Oct. 2002;81(10):770-5.
Tacks, L., et al.,Idiopathic toe walking: Treatment with botulinum toxin A injection, Dev Med Child Neurol 2002;44(Suppl 91):6.
Weigand, et al.,Naunyn-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165.
Allergan Inc.
Donovan Stephen
Kam Chih-Min
Nassif Claude L.
Voet Martin
LandOfFree
Buttock deformity treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Buttock deformity treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Buttock deformity treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4006143